J
Just-Evotec Biologics
Life changing protein therapeutics
About Just-Evotec Biologics
Just-Evotec Biologics operates as a contract development and manufacturing organization (CDMO) with a mission to expand global access to biotherapeutics. The company was founded in 2014 as Just Biotherapeutics, with Dr. James (Jim) Thomas as a co-founder and CEO. Dr. Thomas brought extensive experience from leadership roles at Amgen, Immunex, and Genentech, where he contributed to the advancement of major therapeutics like Enbrel and Repatha. His career has centered on developing technologies for large-scale manufacturing of recombinant proteins. Just Biotherapeutics initially received backing from investors including ARCH Venture Partners, Merck & Co., Lilly Asia Ventures, and the Bill & Melinda Gates Foundation, aligning with its goal to reduce the cost of protein therapeutics.
In a significant milestone, Hamburg-based Evotec SE acquired Just Biotherapeutics in July 2019 for a total consideration of up to $90 million. The acquisition integrated Just.Bio's biologics capabilities with Evotec's small molecule expertise, creating a comprehensive R&D and manufacturing partner for the pharmaceutical industry. Following the acquisition, Dr. Thomas joined Evotec's leadership as Global Head of Biotherapeutics and President of U.S. Operations. Now operating as a wholly-owned subsidiary of Evotec, the company serves a diverse client base, from biotech startups to large pharmaceutical companies and government organizations, offering solutions for discovery, development, and manufacturing of biologics.
The core of Just-Evotec Biologics' offering is its proprietary J.DESIGN technology platform. This integrated, data-driven system utilizes machine learning and artificial intelligence across the entire development lifecycle, from molecular design to manufacturing. The platform aims to accelerate development timelines, de-risk the process, and substantially lower production costs. A key component is its continuous manufacturing process, housed in modular, automated facilities known as J.PODs. These facilities are designed to be more flexible, cost-effective, and faster to build than traditional manufacturing plants. They enable highly intensified, continuous production of biologics at various scales, from clinical to commercial, within a single facility. The company operates J.POD facilities in Redmond, Washington, and Toulouse, France, providing a global manufacturing network. Business models are flexible, ranging from standard fee-for-service contracts to strategic partnerships and technology licensing, allowing partners to integrate the J.POD system into their own operations.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 605
- Open positions
- None listed
- Dealroom signal
- 80.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Drug Development, Biotech and Pharma, Techbio, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Dec 2025 | $0 | — | Sandoz | ↗ |
| GRANT✓Other financing | Oct 2020 | $0 | — | Bill & Melinda Gates Foundation | — |
Growth signals
Latest recorded traffic for Just-Evotec Biologics is 670 monthly website visits, down 52.1% over the last three months. Just-Evotec Biologics's team grew 97.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Just-Evotec Biologics in the Seattle ecosystem
The Just-Evotec Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Merck & Co.
Lilly Asia Ventures
ARCH Venture Partners
Bill & Melinda Gates Foundation
Other known investors2 additional known investors
Evotec
Sandoz
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Just-Evotec Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Just-Evotec Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










